Description du projet Virtual Physiological HumanNeoMark will record and combine heterogeneous clinical, laboratory, molecular and imaging data to develop a data integration environment facilitating multiscale and multilevel modelling.Objectives of the projectThe clinical problemThe continuous improvement in treatment protocols for neoplastic diseases has substantially increased the number of patients who achieve a complete disappearance of the disease after treatment. At this stage there are no clinical, laboratory or imaging evidences of the neoplastic mass, but there can still be invisible residual disease that can evolve overtime and metastasize. A strict follow-up is usually undertaken and adjuvant treatments are planned to reduce the risk of disease reoccurrence, however they have important side-effects that may harm also patients who are already completely recovered. Knowing in advance which patients have the higher risk of disease reoccurrence would be important to focus resources and initiate adjuvant treatments only in a limited, high-risk subgroup of patients and would allow starting an appropriate treatment in time with the potential to improve patient survival and quality of life.NeoMark will pursue the identification of imaging and genomic/ proteomic markers aimed at modelling recurrence of neoplastic disease with two major clinical/scientific purposes:1. identify subjects at higher risk of reoccurrence after reaching remission;2. early diagnose the presence of a reoccurrence.The technical target of NeoMark will be the development of two functional environments: one for the definition of biomarker profiles and one for the follow-up of the evolution of the disease.Expected Results & ImpactsOral cancer holds the eight position in the cancer incidence ranking worldwide, squamous cell carcinoma representing 5% of all cancers for men and 2% for women (WHO). Patients with oral cancer have to deal with the impact of the disease and its treatment on physical appearance and on the ability to eat and to speak, with a significant decrease of the quality of life. Despite advances in salvage treatment of patients with recurrent cancer, outcomes for re-treatment are generally poor. Hence the importance of the identification of specific “markers” for oral cancer whose appearance during follow-ups will enable early and softer interventions and decrease the risks of death. NeoMark expects to develop a system able to early detect the “markers” specific for oral cancer and so enable:• early and more specific diagnosis of cancer reoccurrences;• more targeted and effective interventions based on the patient-specific disease profile;• avoiding unnecessary treatments for patients at very low risk of reoccurrence;• optimising the work of physicians and the usage of resources;• improving the scientific and medical knowledge on oral cancer processes;• improve patients’ quality of life;• increase the life duration for patients with cancer reoccurrence. Afficher les objectifs du projet Masquer les objectifs du projet NeoMark will perform research in the integration of heterogeneous clinical, laboratory, molecular and imaging data to develop a data integration environment facilitating multiscale and multilevel modeling, aimed at advancing models and methods currently in use to predict neoplastic reoccurrences, and to apply it to the study of oral cancer.Specifically the scientific target will be to apply this multi-level data integration environment to the monitoring of the disease after remission, in order to early identify local or metastatic reoccurrence of the disease.The technical target will be the development of two functional envirnments: one for the definition of biomarker profiles and one for the follow-up of the evolution of the disease. They will be based on the "fusion" of information from clinical data from health records and standard laboratory markers; from histological data from tumor mass specimens; from high-throughput genomic data from tumor tissue specimens, profiling gene expression at whole-genome level by oligo-RNA microarrays; from high-throughput genomic data from circulating cells specimens (whole blood sample), profiling gene expression at whole-genome level by oligo-RNA microarrays; from imaging data of the prime tumor mass (and secondary localizations if present) through imaging techniques, including image fusion, where relevant.The outcomes of the project will be validated in two primary Clinical Centres in Spain and in Italy.In this phase the early exploitation of NeoMark will also be assessed through the use of a RT-PCR platform to develop highly individual diagnostic tests to be used both at the time of first diagnosis, as well as for reoccurrence identification. Champ scientifique natural sciencesbiological sciencesgeneticsmedical and health sciencesclinical medicineoncology Programme(s) FP7-ICT - Specific Programme "Cooperation": Information and communication technologies Thème(s) ICT-2007.5.3 - Virtual physiological human Appel à propositions FP7-ICT-2007-2 Voir d’autres projets de cet appel Régime de financement CP - Collaborative project (generic) Coordinateur AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA Contribution de l’UE € 707 776,00 Adresse VIA GRAMSCI 14 43100 Parma Italie Voir sur la carte Région Nord-Est Emilia-Romagna Parma Type d’activité Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Contact administratif Michele MALANCA (Mr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée Participants (9) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV Allemagne Contribution de l’UE € 399 663,00 Adresse HANSASTRASSE 27C 80686 Munchen Voir sur la carte Région Bayern Oberbayern München, Kreisfreie Stadt Type d’activité Research Organisations Contact administratif Christoph Schulte (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSIDAD POLITECNICA DE MADRID Espagne Contribution de l’UE € 172 404,00 Adresse CALLE RAMIRO DE MAEZTU 7 EDIFICIO RECTORADO 28040 Madrid Voir sur la carte Région Comunidad de Madrid Comunidad de Madrid Madrid Type d’activité Higher or Secondary Education Establishments Contact administratif GONZALO LEON (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée FUNDACION MD ANDERSON INTERNATIONAL ESPANA Espagne Contribution de l’UE € 205 190,00 Adresse CALLE GOMEZ HEMANS 2 28033 Madrid Voir sur la carte Région Comunidad de Madrid Comunidad de Madrid Madrid Type d’activité Research Organisations Contact administratif ISABEL CRESPO (Ms.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée PANEPISTIMIO IOANNINON Grèce Contribution de l’UE € 310 000,00 Adresse PANEPISTEMIOYPOLE PANEPISTEMIO IOANNINON 45110 Ioannina Voir sur la carte Région Βόρεια Ελλάδα Ήπειρος Ιωάννινα Type d’activité Higher or Secondary Education Establishments Contact administratif GEORGIOS DETSIKAS (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PLANET S.A Participation terminée Grèce Contribution de l’UE € 184 912,00 Adresse LOUISE RIENCOURT 64, APOLLON TOWER 11523 ATHENS Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif NIKOLAOS KOUTRETSIS (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée ISTITUTI FISIOTERAPICI OSPITALIERI Italie Contribution de l’UE € 63 000,00 Adresse VIA CHIANESI 53 00144 Roma Voir sur la carte Région Centro (IT) Lazio Roma Type d’activité Other Contact administratif ENRICO DEL BAGLIVO (Mr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée STMICROELECTRONICS SRL Italie Contribution de l’UE € 210 314,00 Adresse VIA C.OLIVETTI 2 20864 Agrate Brianza Voir sur la carte Région Nord-Ovest Lombardia Monza e della Brianza Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif MARIA GRAZIA PODESTA' (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée MULTIMED S.R.L. Italie Contribution de l’UE € 357 600,00 Adresse VIA PORTINARI DEL PO 21 26100 CREMONA Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Diego Ardigò (Dr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée LINK CONSULTING - TECNOLOGIAS DE INFORMACAO S.A. Portugal Contribution de l’UE € 285 741,00 Adresse AVENIDA DUQUE D'AVILA 23 1000-138 LISBOA Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Pedro Sousa (Prof.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée